A Phase 1 Randomized, Observer-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Candidate Human Cytomegalovirus Vaccine (VBI-1501) in Healthy Adults

Trial Profile

A Phase 1 Randomized, Observer-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Candidate Human Cytomegalovirus Vaccine (VBI-1501) in Healthy Adults

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Oct 2017

At a glance

  • Drugs VBI 1501A (Primary)
  • Indications Cytomegalovirus infections
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors VBI Vaccines
  • Most Recent Events

    • 11 Oct 2017 According to a VBI Vaccines media release, data from this trial will be highlighted during a presentation at the World Vaccine Congress Europe 2017.
    • 27 Jul 2017 According to a a VBI Vaccines media release, final safety and immunogenicity data is expected in the first half of 2018.
    • 27 Jul 2017 Interim results were published in a VBI Vaccines media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top